Genentech's Evrysdi Two-Year Data Shows Promising Results In Spinal Muscular Atrophy, Most Children Treated Early Reach Key Mobility Milestones
Genentech's Evrysdi Two-Year Data Shows Promising Results In Spinal Muscular Atrophy, Most Children Treated Early Reach Key Mobility Milestones
羅氏旗下的益肌纖維症長達兩年的數據顯示，早期接受治療的大多數兒童達到了關鍵的運動里程碑。
– Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically before 6 weeks of age, with most achieving motor milestones similar to children without SMA –
– 正面數據證實 Evrysdi 在嬰兒6周大之前預症狀治療的兒童中的療效和安全性，大多數實現了類似於沒有SMA的兒童的運動里程碑 –
– All children were able to swallow and feed orally, with none requiring permanent ventilation –
– 所有兒童能夠吞嚥和口服進食，沒有需要永久通氣的 –
– Evrysdi is the only non-invasive SMA therapy and is approved in over 100 countries, with more than 16,000 people with SMA treated globally –
– Evrysdi 是唯一的非侵入性SMA治療藥物，在100多個國家獲批，全球治療SMA的人數超過16,000人 –